serotonin receptors – Page 2

Psychedelics action and schizophrenia

mycolabadmin

This review examines how psychedelic drugs like psilocybin and LSD affect the brain, particularly through serotonin receptors. While these compounds can produce psychosis-like symptoms similar to schizophrenia, they also promote brain plasticity and growth of neural connections. The article discusses whether psychedelics could potentially treat negative symptoms and cognitive problems in schizophrenia patients, despite their mind-altering properties, possibly through lower doses or non-hallucinogenic alternatives.

Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward

mycolabadmin

Researchers discovered that a single dose of psilocybin can reduce opioid addiction-related behaviors in male mice by activating serotonin receptors in specific brain circuits, but this effect does not work the same way in females. The study reveals that psilocybin changes how the brain processes opioid rewards and withdrawal symptoms, suggesting psychedelics could become a new treatment approach for opioid addiction. However, important sex differences in how the brain responds mean treatments may need to be tailored differently for men and women.

Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential

mycolabadmin

Scientists discovered that psychedelic drugs work by activating a specific signaling pathway in the brain called the 5-HT2A-Gq pathway. By creating new drug-like molecules, they found that drugs need to strongly activate this particular pathway to produce psychedelic effects like hallucinations. This discovery could help researchers design new psychiatric medicines that have therapeutic benefits without the hallucinogenic side effects that worry doctors and patients.

The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation

mycolabadmin

Researchers tested whether psilocybin, a compound from magic mushrooms, could protect pancreatic β-cells (which produce insulin) from damage caused by high glucose and fat levels. Using laboratory cells, they found that psilocybin reduced β-cell death by preventing apoptosis and showed promise in reducing dedifferentiation (when cells lose their specialized functions). However, psilocybin didn’t restore the cells’ ability to respond to glucose by releasing insulin.

Effects of hallucinogenic drugs on the human heart

mycolabadmin

Hallucinogenic drugs like LSD and psilocybin affect not only the brain but also the heart. These drugs increase heart rate and contractility mainly through specific serotonin and histamine receptors. While these effects might have therapeutic potential for psychiatric conditions, prolonged use can damage heart valves and cause dangerous arrhythmias. Understanding these cardiac effects is crucial for safe medical use and treatment of overdoses.

Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

mycolabadmin

Psilocybin, a compound from certain mushrooms, is being studied as a potential rapid-acting treatment for severe depression that doesn’t respond to standard antidepressants. Unlike conventional antidepressants that take weeks to work, psilocybin shows promise for producing mood improvements within days. The drug works by activating serotonin receptors in the brain and promoting the growth of new neural connections, though researchers are still working to fully understand how it achieves its antidepressant effects.

Molecular insights into the modulation of the 5HT 2A receptor by serotonin, psilocin, and the G protein subunit Gqα

mycolabadmin

This study uses computer simulations to understand how psilocin (the active compound in magic mushrooms) and serotonin interact with a brain receptor called 5HT 2A R. The research shows that both molecules prefer to bind to a deeper part of the receptor rather than a shallower area, and that a protein called Gqα is essential for keeping the receptor in its active state. These findings could help scientists develop better medicines for depression and anxiety.

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain

mycolabadmin

This review examines how psychedelic drugs like LSD and psilocybin might help treat chronic pain conditions such as cluster headaches and phantom limb pain. The researchers found nine studies suggesting these substances could reduce pain by affecting serotonin receptors in the brain. While early results are promising, more rigorous clinical trials are needed before these drugs can become standard pain treatments. The authors note that strict legal restrictions on psychedelics currently limit research opportunities.

Research Topic: serotonin receptors